Patients With Lung Cancer Respond to ‘Did You Smoke?’
“The Living!!! With Lung Cancer Support Group meets virtually twice per month and is moderated by University of Kansas Cancer Center social worker Sarah Bechard. We are dedicated to building survivorship skills for fellow lung cancer patients and their caregivers.”

Adjuvant Furmonertinib Shows Efficacy, Tolerability in EGFR+ NSCLC With High-Risk Factors
“Furmonertinib (AST2818) had efficacy and an acceptable toxicity profile when utilized as adjuvant treatment in EGFR-mutated, stage IA2-IIIA non–small cell lung cancer with high-risk pathological factors who have undergone radical surgery, according to findings from a retrospective study presented at the 2023 ASCO Breakthrough Meeting.”

Looking Across Disciplines to Share the Breadth of Innovation in Cancer Care
”If one looked only at the progress in lung cancer over the last decade, there would be plenty to behold. Long-term efforts to promote smoking cessation and discoveries of druggable targets combined to push lung cancer mortality rates down 5% a year between 2015 and 2019, according to the annual data from the American Cancer Society.”

New Rapid Lung Cancer Screening Using MALDI-MS
“Lung cancer is responsible for 21% of cancer deaths, according to the National Cancer Institute (1). It is vital to create early screening methods with high classification accuracy to detect cancer early in patients.”

Amivantamab Plus Lazertinib May Be a Future Treatment Option for NSCLC
“Targeting biomarkers in patients with non­–small cell lung cancer [NSCLC] continues to be a major avenue of development for combination therapy with long-term results showing the response durability of amivantamab [Rybrevant] and lazertinib [Leclaza] in patients with EGFR-mutated NSCLC, according to data published in the Journal of Clinical Oncology.”

FDA Clears AI-Powered Software for Lung Nodule Detection on X-Rays
“VisiRad XR, which utilizes artificial intelligence (AI) to facilitate diagnosis of suspicious lung masses and nodules on chest X-rays, has garnered 510(k) clearance from the Food and Drug Administration (FDA).”

Why so few get screened for lung cancer, the deadliest cancer in the U.S.
“It was Thanksgiving 2021, and Michael Young was at Target buying a turkey baster. “I’m in the parking lot, and my chest starts to feel like somebody’s sitting on me,” Young recounted. But he didn’t think too much of it and waited until February to tell the doctor about these on-and-off chest pains. “8:30 a.m. Monday morning, the cardiologist calls me and says, ‘We have a problem; we need to talk,’” Young said. The heart scans had found lung cancer.”

Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
“Repotrectinib continued to demonstrate high response rates and durable responses, including robust intracranial responses, in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer who were TKI-naïve or previously treated with one TKI and no chemotherapy.”